News » Medical Marijuana Inc. To Acquire PharmaSphere, Steps Closer to Putting Cannabis In a Pill Bottle





Medical Marijuana Inc. has executed an option to acquire 100% of PharmaSphere LLC, a cutting edge biotechnology company. PharmaSphere has a method of producing high value bio-compounds sourced from cannabis that can be used as active pharmaceutical ingredients. It involves genetically engineered plants.

The GMO cannabis plants are grown in environmentally contained and controlled conditions. These modified plants are producing high amounts of specific compounds, which can be extracted and used as ingredients for future cannabis-derived pharmaceuticals.

“A major concern for sellers of natural product drugs, medical herbs, nutraceuticals, and cosmeceuticals is the unreliable supply of top quality active ingredients as the cultivation of source plants in the field and outdoors is erratic and the quality of extracts is uneven. With the TerraSphere System and state-of-the art extraction, purification and quality control technologies, the company can assure its customers a reliable consistent supply of high quality plant based compounds such as Cannabidiol, Vincristine and Vanblastine” says PharmaSphere in a press release.

Currently, the company is designing facilities to be built for the process. These will likely be built in a country that allows medical marijuana cultivation, such as Israel, China, or France.

MMI plans to close the purchase of PharmaSphere by the end of the fiscal year.

Tags: genetically modified, gmo, medical marijuana, MMJ